Drug Trial Radar · NCT07871721
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
644
Planned (sponsor's estimate)
Start
Jan 11, 2027
Primary completion
Apr 18, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works and how safe it is in participants with active PsA who have not previously received biological medicines. The study will assess whether zasocitnib helps improve symptoms and slows or prevents further joint damage. Participants will have signs of inflammation in their blood and damage in at least two joints of their hands and feet. Participants will receive either zasocitinib or placebo during the first 24 weeks of the study. After week 24, all participants will receive zasocitinib through week 52. Participants will be in the study for up to 61 weeks.
Conditions
- Psoriatic Arthritis
Interventions
PlaceboOther
Zasocitinib matching placebo oral tablet.
ZasocitinibDrug
Zasocitinib oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 24Time frame: At Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.